Classification of Endothelial Dysfunction. Stefano Taddei Department of Internal Medicine University of Pisa, Italy

Size: px
Start display at page:

Download "Classification of Endothelial Dysfunction. Stefano Taddei Department of Internal Medicine University of Pisa, Italy"

Transcription

1 Classification of Endothelial Dysfunction Stefano Taddei Department of Internal Medicine University of Pisa, Italy

2 Pathogenesis of atherosclerosis from endothelial dysfunction to clinical disease endothelial dysfunction PGI EDHF NO plaque growth stimuli-induced vasodilation (e.g, to shear stress) remodeling/ proliferation acute coronary syndrome ischemia / angina pectoris clinical manifestations

3 Vascular effects of principal endothelium-derived substances Healthy conditions CV risk factors Vasodilation Platelet aggregation VSMC migration and proliferation Monocyte adhesion Adhesion molecules expression ET1 NO EDCFs (ET-1; A-II; TXA 2 ; PGH 2 ; O 2 -) Vasoconstriction NO breakdown: Platelet aggregation VSMC migration and proliferation Monocyte adhesion Adhesion molecules expression Each effect is a different aspect of endothelial function or dysfunction

4 Endothelial Pathology Endothelial Dysfunction reduced NO availability (vascular reactivity) Endothelial Activation acquisition of flogistic activity Endothelial Injury and Repair anathomical disruption and rigeneration of endothelial cells

5 Markers and clinical significance of endothelial pathology ENDOTHELIAL DYSFUNCTION NO NO2/NO3 and other plasma nitrosylated species ADMA Evaluation of vascular reactivity ENDOTHELIAL ACTIVATION adhesion molecules: E-selectin, P-selectin, ICAM-1, VCAM-1 Regulators of thrombosis: tpa, PAI-1 ENDOTHELIAL DAMAGE vwf soluble thrombomodulin circulating endothelial cells endothelial microparticles ENDOTHELIAL REPAIR circulating endothelial progenitor cells

6 Markers and clinical significance of endothelial pathology ENDOTHELIAL DYSFUNCTION NO NO2/NO3 and other plasma nitrosylated species ADMA Evaluation of vascular reactivity ENDOTHELIAL ACTIVATION adhesion molecules: E-selectin, P-selectin, ICAM-1, VCAM-1 Regulators of thrombosis: tpa, PAI-1 ENDOTHELIAL DAMAGE vwf soluble thrombomodulin circulating endothelial cells endothelial microparticles ENDOTHELIAL REPAIR circulating endothelial progenitor cells

7 Plasma ADMA is significantly associated with all-cause mortality The Framingham Offspring study Böger RH et al Circulation 2009

8 ADMA as a prospective marker of CV disease and mortality High risk Intermediate risk Low risk general population Boger RH et al. Pharmacological Research 2009

9 Vascular Reactivity Vascular response to stimulation or inhibition of endothelial function Selectivity for vessel type and vascular district Large availability of agonists and antagonists Strong association with intermediate organ damage and clinical endpoints

10 Effect of aging on endothelium-dependent vasodilation in the forearm microcirculation Normotensive Subjects (N=43) Taddei S et al. Circulation 1995

11 Normotensive Subjects Essential Hypertensive Patients FBFD% saline L-NMMA Ouabain * p<0.05 * Control Vitamin C * * * * * 0 BRADYKININ BRADYKININ BRADYKININ µg/100 ml/min Taddei S et al Circulation 1999

12 Coronary endothelial dysfunction in hypertensive patients Role of oxidative stress Solzbach U et al, Circulation 1997

13 Maximal Achetilcholine-induced FBF increase ( D%) Association between endothelial dysfunction and atherosclerosis CORONARY ARTERIES CAROTID ARTERIES 2000 r = -.58 p< ,6 0,9 1,2 1,5 1,8 2,1 INTIMA-MEDIAL THICKNING (mm) Zeiher AM et al. Circulation 1994 Ghiadoni L et al. Hypertension 1998

14 Endothelial Function Assessed by Vascular Reactivity and Cardiac Events Multivariant analysis of hazard ratio of present studies reporting association between coronary or peripheral endothelial function and cardiovascular events Lerman A & Zeiher A Circulation 2005

15 Vascular effects of principal endothelium-derived substances Healthy conditions CV risk factors Vasodilation Platelet aggregation VSMC migration and proliferation Monocyte adhesion Adhesion molecules expression ET1 NO EDCFs (ET-1; A-II; TXA 2 ; PGH 2 ; O 2 -) Vasoconstriction NO breakdown: Platelet aggregation VSMC migration and proliferation Monocyte adhesion Adhesion molecules expression

16 t-pa balance (ng/100 ml/min) Effect of NO-synthase blockade by L-NMMA on t-pa release in normotensive subjects and essential hypertensive patients ACh induced release 1.0 Normotensive subjects Hypertensive patients 0.5 * 0 ACh ACh + L-NMMA ACh + L- NMMA Giannarelli C et al Hypertension 2007

17 tpa release ng/100ml/min Effect of bradykinin on tpa release in the presence of saline or sulfaphenazole in hypertensive patients Hypertensive Patients Saline Sulfaphenazole p<0.01 vs BDK+saline * 0 Baseline Bradykinin Giannarelli C et al Circulation 2009

18 Relaxation t-pa release Smooth muscle cells Endothelial cells NO EDHF Bradykinin

19 Markers and clinical significance of endothelial pathology ENDOTHELIAL DYSFUNCTION NO NO2/NO3 and other plasma nitrosylated species ADMA ENDOTHELIAL ACTIVATION adhesion molecules: E-selectin, P-selectin, ICAM-1, VCAM-1 regulators of thrombosis: tpa, PAI-1 ENDOTHELIAL DAMAGE vwf soluble thrombomodulin circulating endothelial cells endothelial microparticles ENDOTHELIAL REPAIR circulating endothelial progenitor cells

20 Endothelial activation represents a switch from a quiescent phenotype toward one that involves the host defense response Constans J et al Clinica Chimica Acta 2006

21 Soluble e-selectin in essential hypertension: a correlate of vascular structural changes De Caterina R et al Am J Hypertens 2001

22 Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis The odds ratio for CHD were 1 68 (95% Cl ) for ICAM-1 and 1 27 ( ) for E-selectin, but became not significant after adjustment for some classic coronary risk factors and indicators of socioeconomic status. The measurement of adhesion molecules is unlikely to add much predictive information to that provided by more established risk factors. Malik I et al Lancet 2001

23 Markers and clinical significance of endothelial pathology ENDOTHELIAL DYSFUNCTION NO NO2/NO3 and other plasma nitrosylated species ADMA ENDOTHELIAL ACTIVATION adhesion molecules: E-selectin, P-selectin, ICAM-1, VCAM-1 Regulators of thrombosis: tpa, PAI-1 ENDOTHELIAL DAMAGE Von Willebrand Factor soluble thrombomodulin circulating endothelial cells endothelial microparticles ENDOTHELIAL REPAIR circulating endothelial progenitor cells

24 Von Willebrand Factor, Soluble P-Selectin, and Target Organ Damage in Hypertension A Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) * * p<0.05 * * p<0.05 * Hypertensive patients Spencer CGC et al Hypertension 2002

25 A comparison of FMD and VWF as markers of endothelial cell function in health and in hypertension A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial r=0.517, p < vwf and FMD both correlated with 10-year cardiovascular risk using the Framingham equation (vwf, r=0.48, p< 0.001; FMD, r =0.624, p< 0.001). Felmeden DC et al Blood Coagulation and Fibrinolysis 2003

26 Soluble thrombomodulin Thrombomodulin (TM) is specifically expressed by endothelial cells Soluble TM can be reliably measured by ELISA Controversial clinical significance: TM is released from injured endothelial cells high levels indicate a greater extent of endothelial damage? TM plays a role as a protein C cofactor and has anticoagulant activity high levels may be protective?

27 High Soluble thrombomodulin predicts recurrence after CAD and mortality after stroke 54 patients who had survived a myocardial infarction Soluble thrombomodulin was 65+/-24 ng/ml in patients who suffered an end-point and was 49+/-19 ng/ml in patients who were free of an end-point (p=0.009). Using life tables, soluble thrombomodulin had a significant effect on survival free of an end-point (p=0.011). Blann AD et al. Eur J Haematol patients with previous brain infarction 5 years follow up Soluble thrombomodulin among the upper tertile confers risk of recurrence of 2.04 ( ), as compared to the lower tertile Olivot GM et al Stroke 2004

28 Rate ratio of incident coronary heart disease Low stm predicts CHD in healthy individuals The ARIC study < >66.3 Quintiles of soluble thrombomodulin (ng/ml) Possible explanation: In healthy people, concentrations of soluble thrombomodulin may reflect the quantity of thrombomodulin expressed on the endothelial surface. Increased expression of thrombomodulin will increase production of activated protein C, which suppresses the coagulation reaction by degrading factors Va and VIIIa. Salomaa V et al Lancet 1999

29 Endothelial Dysfunction (FMD) and Damage (CEC) in Congestive Heart Failure r=0.423, p=0.002 Chong AY et al. Circulation. 2004;110:

30 Circulating endothelial cells and prognosis in 156 patients with acute coronary syndromes Numbers of circulating endothelial cells (CECs) on admission according to diagnosis and compared with patients with stable angina and healthy control subjects. STEMI indicates ST-segment elevation myocardial infarction; NSTEMI, non-stemi; UAP, unstable angina pectoris; SA, stable angina. Kaplan-Meier cumulative 1-year event-free survival curves between more than median versus less than median values of (A) CECs at 48 hours Lee KW et al. Blood 2005;105:526 32

31 Circulating endothelial cells in hypertension and acute ischaemic stroke 29 hypertensive patients with previous stroke, 30 hypertensive patients and 30 normotensive controls Patients with an acute ischaemic stroke had significantly higher numbers of CECs/ml of blood (p<0.001) plasma vwf (p=0.008), soluble E-selectin (p=0.002) and higher SBP as compared to the other groups The number of CECs significantly correlated with soluble E-selectin (r=0.432, p<0.001) and vwf (r=0.349, p=0.001) but not with SBP (r=0.198, p=0.069) Nadar SK et al, Thromb Haemost 2005; 94:

32 Microparticles Microparticles are submicron vesicles derived from cell membranes They are shed from plasma membranes in response to cell activation, injury, and/or apoptosis Microparticles originating from platelets, endothelial cells and leukocytes have been most extensively studied Chironi NG et al, Cell Tissue Res (2009) 335:

33 Circulating microparticles (events/µl) Circulating Endothelial Microparticles Are Associated with Vascular Dysfunction in Patients with End-Stage Renal Failure Flow cytometry analysis of platelet-free plasma from 44 patients with ESRF indicated that circulating levels of Annexin V+ microparticles were increased compared with 32 healthy subjects, as were levels of microparticles derived from endothelial cells (three-fold), platelets (16.5-fold), and erythrocytes (1.6-fold). Platelet-derived MP Endothelium-derived MP Endothelium-derived MP Erythrocytes-derived MP End stage renal failure Healthy subjects Amabile N et al. J Am Soc Nephrol 16: , 2005

34 Markers and clinical significance of endothelial pathology ENDOTHELIAL DYSFUNCTION NO NO2/NO3 and other plasma nitrosylated species ADMA ENDOTHELIAL ACTIVATION adhesion molecules: E-selectin, P-selectin, ICAM-1, VCAM-1 Regulators of thrombosis: tpa, PAI-1 ENDOTHELIAL DAMAGE vwf soluble thrombomodulin circulating endothelial cells endothelial microparticles ENDOTHELIAL REPAIR circulating endothelial progenitor cells

35 Conclusions Classification of endothelial dysfunction is important to understand the pathophysiology of atherosclerotic disease and in the next future might be useful for a better determination of CV risk and the effectiveness of treatment. However, at the present time, the different aspects of endothelial dysfunctions are not related to a specifc clinical significance. Further investigation is necessary to establish the exact relationship between the different types of endothelial alterations and the development of CV disease. In addition, no large scale intervention trials are available to consider endothelial dysfunction as a target of CV treatment.

The Study of Endothelial Function in CKD and ESRD

The Study of Endothelial Function in CKD and ESRD The Study of Endothelial Function in CKD and ESRD Endothelial Diversity in the Human Body Aird WC. Circ Res 2007 Endothelial Diversity in the Human Body The endothelium should be viewed for what it is:

More information

Antiplatelet agents treatment

Antiplatelet agents treatment Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic

More information

ROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret

ROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as

More information

The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction

The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction Cardiovascular Center, Korea University Guro Hospital 2007. 4. 20 Seung-Woon Rha, MD, PhD Introduction 1.

More information

Endothelial dysfunction in hypertension: from bench to bedside

Endothelial dysfunction in hypertension: from bench to bedside Endothelial dysfunction in hypertension: from bench to bedside Stefano Taddei Department of Clinical and Experimental Medicine University of Pisa, Italy Press Release: The 1998 Nobel Prize in Physiology

More information

La Trombosi Arteriosa

La Trombosi Arteriosa La Trombosi Arteriosa Prof. Giovanni Davì Medicina Interna Chieti Platelet activation and thrombosis Harrison 19 edizione Platelets are essential for primary hemostasis and repair of the endothelium They

More information

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and

More information

Supplementary table to Bennett et al. Peripheral arterial disease and Virchow s triad (Thromb Haemost 2009; 101.6)

Supplementary table to Bennett et al. Peripheral arterial disease and Virchow s triad (Thromb Haemost 2009; 101.6) Supplementary table to ennett et al. Peripheral arterial disease and Virchow s triad (Thromb Haemost 2009; 101.6) Supplementary Table 1: Examples of Recent studies reporting positive associations between

More information

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents

More information

Cho et al., 2009 Journal of Cardiology (2009), 54:

Cho et al., 2009 Journal of Cardiology (2009), 54: Endothelial Dysfunction, Increased Carotid Artery Intima-media Thickness and Pulse Wave Velocity, and Increased Level of Inflammatory Markers are Associated with Variant Angina Cho et al., 2009 Journal

More information

Invited Review. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases

Invited Review. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases Histol Histopathol (2000) 15: 557-571 Histology and Histopathology Cellular and Molecular Biology Invited Review Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular

More information

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital

More information

Targeting intracellular arginine / asymmetric dimethylarginine (ADMA).

Targeting intracellular arginine / asymmetric dimethylarginine (ADMA). Targeting intracellular arginine / asymmetric dimethylarginine (ADMA). From bench to practice: Novel anti-atherogenic strategies to improve endothelial function Rainer H. Böger, M.D. Institute of Clinical

More information

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System

More information

Acute coronary syndrome. Dr LM Murray Chemical Pathology Block SA

Acute coronary syndrome. Dr LM Murray Chemical Pathology Block SA Acute coronary syndrome Dr LM Murray Chemical Pathology Block SA13-2014 Acute myocardial infarction (MI) MI is still the leading cause of death in many countries It is characterized by severe chest pain,

More information

Annals of RSCB Vol. XVI, Issue 1

Annals of RSCB Vol. XVI, Issue 1 THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;

More information

Clinical Significance of Aldosterone Levels and Low Grade Inflammation in Patients with Coronary Vasospasm

Clinical Significance of Aldosterone Levels and Low Grade Inflammation in Patients with Coronary Vasospasm Clinical Significance of Aldosterone Levels and Low Grade Inflammation in Patients with Coronary Vasospasm Department of Cardiology Keiji Inoue Akira Ueoka, Naoki Maruyama, Yoshiaki Shimoda, Eigo Kishita,

More information

The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories

The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury

More information

The effect of carotenoids and flavones on oxidative stress in endothelial cells

The effect of carotenoids and flavones on oxidative stress in endothelial cells The effect of carotenoids and flavones on oxidative stress in endothelial cells Esther Paran MD Hypertension Research Center Faculty of Health Sciences Ben-Gurion University Cardiovascular Mortality Risk

More information

LOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING

LOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin

More information

Novel Markers of Arterial Dysfunction

Novel Markers of Arterial Dysfunction 혈관연구회창립심포지움, 3 월 3 일, 2005 Novel Markers of Arterial Dysfunction Kwang Kon Koh, MD, FACC, FAHA Cardiology Gachon Medical School Incheon, Korea Atherosclerosis: A progressive process PHASE I: Initiation

More information

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Dyslipidemia Endothelial dysfunction Free radicals Immunologic ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and

More information

Figure 13-1: Antiplatelet Action of Aspirin (Modified After Taneja et.al 2004) ASPIRIN RESISTANCE

Figure 13-1: Antiplatelet Action of Aspirin (Modified After Taneja et.al 2004) ASPIRIN RESISTANCE CHAPTER 13 ASPIRIN Action Aspirin Resistance Aspirin Dose Therapeutic Efficacy - Secondary prevention - Acute coronary syndromes - Primary prevention Limitations and Side Effects Aspirin Aspirin should

More information

Cardiovascular Protection and the RAS

Cardiovascular Protection and the RAS Cardiovascular Protection and the RAS Katalin Kauser, MD, PhD, DSc Senior Associate Director, Boehringer Ingelheim Pharmaceutical Inc. Micardis Product Pipeline Scientific Support Ridgefield, CT, USA Cardiovascular

More information

Inflammation plays a major role in atherosclerosis, 1 and

Inflammation plays a major role in atherosclerosis, 1 and Soluble P-Selectin and the Risk of Future Cardiovascular Events Paul M. Ridker, MD; Julie E. Buring, ScD; Nader Rifai, PhD Background P-selectin, a cell-surface adhesion molecule involved in leukocyte

More information

Platelet function in diabetes

Platelet function in diabetes Platelet function in diabetes Agneta Siegbahn, MD, PhD, FESC Professor Clinical Coagulation Science Department of Medical Sciences and Uppsala Clinical Research Center Uppsala University Disclosures: None

More information

PATIENTS AND METHODS:

PATIENTS AND METHODS: BACKGROUND: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by erosive synovitis that involves peripheral joints and implicates an important influence in the quality

More information

Endothelium. A typical endothelial cell is about 30mm long, Accounts for 1% or less of the arterial weight

Endothelium. A typical endothelial cell is about 30mm long, Accounts for 1% or less of the arterial weight Endothelium Discovered in 1845 A typical endothelial cell is about 30mm long, 10mm wide, and 0.2 3 mm thick Accounts for 1% or less of the arterial weight As recently as the late 1960s it was thought of

More information

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with

More information

Aging is a well-documented cardiovascular risk factor.

Aging is a well-documented cardiovascular risk factor. Physical Activity Prevents Age-Related Impairment in Nitric Oxide Availability in Elderly Athletes Stefano Taddei, MD; Fabio Galetta, MD; Agostino Virdis, MD; Lorenzo Ghiadoni, MD; Guido Salvetti, MD;

More information

PHM142 Lecture 4: Platelets + Endothelial Cells

PHM142 Lecture 4: Platelets + Endothelial Cells PHM142 Lecture 4: Platelets + Endothelial Cells 1 Hematopoiesis 2 Platelets Critical in clotting - activated by subendothelial matrix proteins (e.g. collagen, fibronectin, von Willebrand factor) and thrombin

More information

Effects of the angiotensin II type-1 receptor antagonist telmisartan on endothelial activation induced by advanced glycation endproducts

Effects of the angiotensin II type-1 receptor antagonist telmisartan on endothelial activation induced by advanced glycation endproducts Effects of the angiotensin II type-1 receptor antagonist telmisartan on endothelial activation induced by advanced glycation endproducts Serena Del Turco, Teresa Navarra, Giuseppina Basta, Raffaele De

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

PCTH 400. Endothelial dysfunction and cardiovascular diseases. Blood vessel LAST LECTURE. Endothelium. High blood pressure

PCTH 400. Endothelial dysfunction and cardiovascular diseases. Blood vessel LAST LECTURE. Endothelium. High blood pressure PCTH 400 LAST LECTURE Endothelial dysfunction and cardiovascular diseases. Classic Vascular pharmacology -chronic -systemic Local Vascular pharmacology -acute -targeted High blood pressure Blood pressure

More information

Adults With Diagnosed Diabetes

Adults With Diagnosed Diabetes Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et

More information

Conflicts of interest. Very balanced Lilly and team, AZ and BMS

Conflicts of interest. Very balanced Lilly and team, AZ and BMS Conflicts of interest Very balanced Lilly and team, AZ and BMS Distal microcirculation receives platelet microparticles Release TxA 2 and plugs microcapillaries Healthy vascular endothelium Prevents (antithrombotic

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

ATHEROSCLEROSIS زيد ثامر جابر. Zaid. Th. Jaber

ATHEROSCLEROSIS زيد ثامر جابر. Zaid. Th. Jaber ATHEROSCLEROSIS زيد ثامر جابر Zaid. Th. Jaber Objectives 1- Review the normal histological features of blood vessels walls. 2-define the atherosclerosis. 3- display the risk factors of atherosclerosis.

More information

Endothelial dysfunction Venous insufficiency and varices

Endothelial dysfunction Venous insufficiency and varices Endothelial dysfunction Venous insufficiency and varices Roman Gardlík, MD, PhD Institute of Pathophysiology Institute of Molecular Biomedicine romangardlik@gmail.com www.imbm.sk Endothelium A type of

More information

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.

More information

LXIV: DRUGS: 4. RAS BLOCKADE

LXIV: DRUGS: 4. RAS BLOCKADE LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations

More information

ATEF ELBAHRY,FACA,FICA,MISCP,FVBWG.

ATEF ELBAHRY,FACA,FICA,MISCP,FVBWG. Hyperglycemia and Coronary Events: where is the link? ATEF ELBAHRY,FACA,FICA,MISCP,FVBWG. Cardiovascular (CV) disease is the primary complication of diabetes ~65% of deaths are due to CV disease Coronary

More information

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD Hein J. Verberne Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands International Conference

More information

New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen

New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Variability of residual platelet

More information

Ischemic heart disease

Ischemic heart disease Ischemic heart disease Introduction In > 90% of cases: the cause is: reduced coronary blood flow secondary to: obstructive atherosclerotic vascular disease so most of the time it is called: coronary artery

More information

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck. DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets

More information

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries

More information

12/18/2009 Resting and Maxi Resting and Max mal Coronary Blood Flow 2

12/18/2009 Resting and Maxi Resting and Max mal Coronary Blood Flow 2 Coronary Artery Pathophysiology ACS / AMI LeRoy E. Rabbani, MD Director, Cardiac Inpatient Services Director, Cardiac Intensive Care Unit Professor of Clinical Medicine Major Determinants of Myocardial

More information

Part IV Antithrombotics, Anticoagulants and Fibrinolytics

Part IV Antithrombotics, Anticoagulants and Fibrinolytics Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System

More information

Subclinical inflammation and peripheral artery disease. Luigi M Biasucci, M.D. Institute of Cardiology Catholic University Rome, ITALY

Subclinical inflammation and peripheral artery disease. Luigi M Biasucci, M.D. Institute of Cardiology Catholic University Rome, ITALY Subclinical inflammation and peripheral artery disease Luigi M Biasucci, M.D. Institute of Cardiology Catholic University Rome, ITALY ESC Congress 2010 Conflict of interest Research grants:sanofi-aventis,

More information

Value of cardiac rehabilitation Prof. Dr. L Vanhees

Value of cardiac rehabilitation Prof. Dr. L Vanhees Session: At the interface of hypertension and coronary heart disease haemodynamics, heart and hypertension Value of cardiac rehabilitation Prof. Dr. L Vanhees ESC Stockholm August 2010 Introduction There

More information

Disclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin

Disclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,

More information

Diabetes and the Heart

Diabetes and the Heart Diabetes and the Heart Association of Specialty Professors April 4, 2013 Jorge Plutzky, MD Co-Director, Preventive Cardiology Director, The Lipid Clinic Cardiovascular Division Brigham and Women s Hospital

More information

The use of pathology surrogate markers in Fabry Disease. Beth L. Thurberg MD PhD Vice President of Pathology Genzyme

The use of pathology surrogate markers in Fabry Disease. Beth L. Thurberg MD PhD Vice President of Pathology Genzyme Disclaimer: Presentation slides from the Rare Disease Workshop Series are posted by the EveryLife Foundation for Rare Diseases for educational purposes only. They are for use by drug development professionals

More information

Choosing Study Outcomes that Reflect Cardiovascular Disease: From Biomarkers to Burden of Disease. Greg Wellenius Joel Kaufman

Choosing Study Outcomes that Reflect Cardiovascular Disease: From Biomarkers to Burden of Disease. Greg Wellenius Joel Kaufman Choosing Study Outcomes that Reflect Cardiovascular Disease: From Biomarkers to Burden of Disease Greg Wellenius Joel Kaufman Framework for Choosing Subclinical Outcomes To Study What clinical outcomes

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular

More information

Slide notes: References:

Slide notes: References: 1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory

More information

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,

More information

Correlation of novel cardiac marker

Correlation of novel cardiac marker Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely

More information

12 Lead EKG Chapter 4 Worksheet

12 Lead EKG Chapter 4 Worksheet Match the following using the word bank. 1. A form of arteriosclerosis in which the thickening and hardening of the vessels walls are caused by an accumulation of fatty deposits in the innermost lining

More information

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without

More information

Pathophysiology of Coronary Microvascular Dysfunction

Pathophysiology of Coronary Microvascular Dysfunction Pathophysiology of Coronary Microvascular Dysfunction Cheol Woong Yu, MD, PhD Cardiology Department Division of Internal Medicine Korea University Anam Hospital. Etiologies of Chest Pain without obstructive

More information

PATHOPHYSIOLOGY OF ACUTE CORONARY SYNDROMES

PATHOPHYSIOLOGY OF ACUTE CORONARY SYNDROMES PATHOPHYSIOLOGY OF ACUTE CORONARY SYNDROMES Brian R. Holroyd, MD, FACEP, FRCPC Professor and Director, Division of Emergency Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton,

More information

Impact de la convection

Impact de la convection Dysfonction Endothéliale, et toxines urémiques des patients dialysés Impact de la convection Ziad A. Massy Ambroise Paré Hospital, University Hospitals Paris Ile de France West, UVSQ, Boulogne Billancourt

More information

DECLARATION OF CONFLICT OF INTEREST. No conflicts of interest

DECLARATION OF CONFLICT OF INTEREST. No conflicts of interest DECLARATION OF CONFLICT OF INTEREST No conflicts of interest University Heart Centre Tübingen Angiogenic actions of platelets Meinrad Gawaz, MD, FESC Tübingen, Germany ESC 2011 Paris GPIb GPIb GPVI TxA2

More information

Endothelium as a part of septic Multiple Organ Dysfunction Syndrome (MODS)-is endocan an answer?

Endothelium as a part of septic Multiple Organ Dysfunction Syndrome (MODS)-is endocan an answer? Endothelium as a part of septic Multiple Organ Dysfunction Syndrome (MODS)-is endocan an answer? Małgorzata Lipinska-Gediga Department of Anaesthesiology and Intensive Therapy Medical University Wroclaw,

More information

CAROTID INTIMA-MEDIA THICKNESS. Dimitrios N. Nikas, MD, PhD, FESC Interventional Cardiologist Ioannina University Hospital

CAROTID INTIMA-MEDIA THICKNESS. Dimitrios N. Nikas, MD, PhD, FESC Interventional Cardiologist Ioannina University Hospital CAROTID INTIMA-MEDIA THICKNESS Dimitrios N. Nikas, MD, PhD, FESC Interventional Cardiologist Ioannina University Hospital I, DIMITRIOS N. NIKAS, MD, PHD, FESC, HAVE NO CONFLICT OF INTEREST TO DECLARE RELATED

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

FOCUS ON CARDIOVASCULAR DISEASE

FOCUS ON CARDIOVASCULAR DISEASE The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.

More information

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Adipose Tissue as an Endocrine Organ. Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University

Adipose Tissue as an Endocrine Organ. Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University Adipose Tissue as an Endocrine Organ Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University Functions of Adipose Tissue Adipose tissue expresses and secretes a variety of bioactive peptides,

More information

Relationship between serum glutathione peroxidase-1activity with endothelial dysfunction level in patients with coronary artery diseases

Relationship between serum glutathione peroxidase-1activity with endothelial dysfunction level in patients with coronary artery diseases Relationship between serum glutathione peroxidase-1activity with endothelial dysfunction level in patients with coronary artery diseases Introduction Reactive oxygen species (ROS),such as superoxide and

More information

Oral Disease as a Risk Factor for Acute Coronary Syndrome Single Center Experience

Oral Disease as a Risk Factor for Acute Coronary Syndrome Single Center Experience 1167 International Journal of Collaborative Research on Internal Medicine & Public Health Oral Disease as a Risk Factor for Acute Coronary Syndrome Single Center Experience Sachin Kumar Amruthlal Jain

More information

Use of Biomarkers for Detection of Acute Myocardial Infarction

Use of Biomarkers for Detection of Acute Myocardial Infarction Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine

More information

Microparticles- Signaling in Atherothrombosis Agneta Siegbahn, MD, PhD, FESC Professor in Coagulation Science

Microparticles- Signaling in Atherothrombosis Agneta Siegbahn, MD, PhD, FESC Professor in Coagulation Science Microparticles- Signaling in Atherothrombosis Agneta Siegbahn, MD, PhD, FESC Professor in Coagulation Science Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University Uppsala,

More information

Stefanos K. Roumeliotis. Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece. Stefanos K.

Stefanos K. Roumeliotis. Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece. Stefanos K. Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece Passive, degenerative accumulation process of Ca ++ /P +++ without treatment options Active, complex, condition:

More information

Thoughtful vs. Dogmatic

Thoughtful vs. Dogmatic Debate on Balloon Assisted Maturation The Biology is Wrong: BAM Won t Work BAM Dr. Rapp Debate BIVF Dr. Lawson Jeffrey H. Lawson, M.D., Ph.D. Departments of Surgery and Pathology Duke University Medical

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t? Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial

More information

High Sensitivity Troponin Improves Management. But Not Yet

High Sensitivity Troponin Improves Management. But Not Yet High Sensitivity Troponin Improves Management But Not Yet Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine

More information

IMMATURE PLATELETS CLINICAL USE

IMMATURE PLATELETS CLINICAL USE HAEMATOLOGY FEBRUARY 217 WHITE PAPER IMMATURE PLATELETS CLINICAL USE Identifying poor antiplatelet drug response and its risks early on Platelets are important cells for repairing endothelial lesions,

More information

V. Roldán, F. Marín, B. Muiña, E. Jover, C. Muñoz-Esparza, M. Valdés, V. Vicente, GYH. Lip

V. Roldán, F. Marín, B. Muiña, E. Jover, C. Muñoz-Esparza, M. Valdés, V. Vicente, GYH. Lip PLASMA VON WILLEBRAND FACTOR LEVELS ARE AN INDEPENDENT RISK FACTOR ADVERSE EVENTS IN HIGH RISK ATRIAL FIBRILLATION PATIENTS TAKING ORAL ANTICOAGULATION THERAPY V. Roldán, F. Marín, B. Muiña, E. Jover,

More information

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in

More information

Asif Serajian DO FACC FSCAI

Asif Serajian DO FACC FSCAI Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac

More information

Arterial Pressure in CKD5 - ESRD Population Gérard M. London

Arterial Pressure in CKD5 - ESRD Population Gérard M. London Arterial Pressure in CKD5 - ESRD Population Gérard M. London INSERM U970 Paris 150 SBP & DBP by Age, Ethnicity &Gender (US Population Age 18 Years, NHANES III) 150 SBP (mm Hg) 130 110 80 Non-Hispanic Black

More information

PEOPLE WITH TYPE 2 diabetes are disproportionately

PEOPLE WITH TYPE 2 diabetes are disproportionately 0163-769X/04/$20.00/0 Endocrine Reviews 25(1):153 175 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/er.2002-0034 Nontraditional Risk Factors for Cardiovascular Disease in Diabetes

More information

Atherothrombosis And Coronary Artery Disease

Atherothrombosis And Coronary Artery Disease Atherothrombosis And Coronary Artery Disease 1 / 6 2 / 6 3 / 6 Atherothrombosis And Coronary Artery Disease Risk factors for coronary artery disease (CAD) were not formally established until the initial

More information

Outline Anti-coagulant and anti-thrombotic drugs Haemostasis and Thrombosis Year 3 Dentistry

Outline Anti-coagulant and anti-thrombotic drugs Haemostasis and Thrombosis Year 3 Dentistry Outline Anti-coagulant and anti-thrombotic drugs Year 3 Dentistry Professor Yotis Senis Cellular Haemostasis y.senis@bham.ac.uk I. Haemostasis and II. Coagulation and anti-coagulants III. Platelets and

More information

Pathophysiology of Cardiovascular System. Dr. Hemn Hassan Othman, PhD

Pathophysiology of Cardiovascular System. Dr. Hemn Hassan Othman, PhD Pathophysiology of Cardiovascular System Dr. Hemn Hassan Othman, PhD hemn.othman@univsul.edu.iq What is the circulatory system? The circulatory system carries blood and dissolved substances to and from

More information

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,

More information

Comparison of Mean Platelet Volume in Acute Myocardial Infarction vs. Normal Coronary Angiography

Comparison of Mean Platelet Volume in Acute Myocardial Infarction vs. Normal Coronary Angiography Global Journal of Health Science; Vol. 8, No. 11; 2016 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Comparison of Mean Platelet Volume in Acute Myocardial Infarction

More information

Arteriosclerosis & Atherosclerosis

Arteriosclerosis & Atherosclerosis Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,

More information

TYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016

TYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016 TYPE II MI KC ACDIS LOCAL CHAPTER March 8, 2016 TYPE 2 MI DEFINITION: Acute coronary syndrome (ACS) encompasses a continuum of myocardial ischemia and infarction, which can make the diagnostic and coding

More information

Association of Mean Platelet Volume and Fibrinogen with Major Cardiovascular Events in Acute Coronary syndrome

Association of Mean Platelet Volume and Fibrinogen with Major Cardiovascular Events in Acute Coronary syndrome International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.11.07, pp 29-36, 2018 Association of Mean Platelet Volume and Fibrinogen with Major Cardiovascular

More information

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III

More information

How to detect early atherosclerosis ; focusing on techniques

How to detect early atherosclerosis ; focusing on techniques How to detect early atherosclerosis ; focusing on techniques Jang-Ho Bae, MD., PhD. Heart Center Konyang University Hospital Daejeon city, S. Korea Surrogates for Atherosclerosis Measures of endothelial

More information

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension In the name of GOD Animal models of cardiovascular diseases: myocardial infarction & hypertension 44 Presentation outline: Cardiovascular diseases Acute myocardial infarction Animal models for myocardial

More information

Ischemic Heart Disease

Ischemic Heart Disease Ischemic Heart Disease Dr Rodney Itaki Lecturer Division of Pathology University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology General Consideration Results from partial

More information

SBP in range of 120 to 140 :no progression or regression of CAD. Sipahi et al., 2006

SBP in range of 120 to 140 :no progression or regression of CAD. Sipahi et al., 2006 Management of Hypertension in Patients with CAD M. Mohsen Ibrahim, MD Cardiology Department- Cairo University 1. What is the optimal BP in patients with hypertension and CAD? 2. What is the minimum safe

More information